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University of California, San Diego, San Diego, CA 92093, USAFibrotic diseases contribute to 45% of deaths in the industrial-
ized world, and therefore a better understanding of the patho-
physiological mechanisms underlying tissue fibrosis is sorely
needed. We aimed to identify novel modifiers of tissue fibrosis
expressed by myofibroblasts and their progenitors in their dis-
ease microenvironment through RNA silencing in vivo. We
leveraged novel biology, targeting genes upregulated during
liver and kidney fibrosis in this cell lineage, and employed small
interfering RNA (siRNA)-formulated lipid nanoparticles tech-
nology to silence these genes in carbon-tetrachloride-induced
liver fibrosis in mice. We identified five genes, Egr2, Atp1a2,
Fkbp10, Fstl1, and Has2, which modified fibrogenesis based
on their silencing, resulting in reduced Col1a1 mRNA levels
and collagen accumulation in the liver. These genes fell
into different groups based on the effects of their silencing
on a transcriptional mini-array and histological outcomes.
Silencing of Egr2 had the broadest effects in vivo and also
reduced fibrogenic gene expression in a human fibroblast cell
line. Prior to our study, Egr2, Atp1a2, and Fkbp10 had not
been functionally validated in fibrosis in vivo. Thus, our results
provide a major advance over the existing knowledge of fibro-
genic pathways. Our study is the first example of a targeted
siRNA assay to identify novel fibrosis modifiers in vivo.Received 3 November 2016; accepted 14 April 2017;
http://dx.doi.org/10.1016/j.omtn.2017.04.014.
7Present address: Jounce Therapeutics, Cambridge, MA 02142, USA
Correspondence: Elisabeth H. Vollmann, Biogen, Inc., Cambridge, MA 02142,
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Pathological tissue fibrosis is the abnormal accumulation of collagen-
rich extracellular matrix (ECM) after a chronic or misregulated
response to injury that progressively disrupts tissue architecture,
leading to tissue stiffness, impaired organ function, and eventually
organ failure. Fibrosis is featured in diverse conditions, accounts
for as much as 45% of all deaths worldwide, and appears to be
increasing in prevalence.1 Fibrosis complications arise in very
different disease settings, from autoimmunity and environmentally
induced inflammation to cancer, spanning multiple organs. To
date, the treatment options are extremely limited for attenuating or
reversing this process. Thus, there is an urgent need to delineate un-
derlying pathological mechanisms that may lead to new therapeutic
approaches.314 Molecular Therapy: Nucleic Acids Vol. 7 June 2017 ª 2017 The Au
This is an open access article under the CC BY-NC-ND license (httpBoth the initiation and persistence of pathological fibrosis involves
the activation and differentiation of progenitors to myofibroblasts,
the key effectors in fibrosis.2 Myofibroblasts play an important role
in executing physiologic tissue repair, leading to matrix deposition,
wound contraction, and healing on one hand, and pathological fibro-
genesis leading to chronic fibrosing conditions on the other.3 Accord-
ingly, prominent molecular pathways in acute tissue repair often
recapitulate their fibrogenic function in chronic fibrotic conditions,
essentially conditions in which wound healing has gone awry; these
include platelet derived growth factor receptor beta (PDGFRb) and
transforming growth factor beta (TGF-b). However, there are still
many gaps in our understanding of the mechanisms underlying fibro-
genesis. Due to their morphology and function, these cells are incred-
ibly difficult to study in vitro. Recently, elegant fate mapping studies
pointed to a role for pericytes as a significant progenitor pool for my-
ofibroblasts after injury in a variety of organ systems.4 Liver pericytes,
also known as hepatic stellate cells (HSCs), have been shown to be the
major progenitor pool for myofibroblasts after carbon tetrachloride
(CCl4)-induced liver injury and fibrosis,
5,6 and gene expression
profiling of these cells isolated at various time points after CCl4
administration identified molecular alterations that might be func-
tionally relevant to fibrogenesis.6 Likewise, myofibroblasts and their
precursors have been transcriptionally profiled during kidney fibrosis
in mice using translational ribosome affinity purification technology.7
Isolation of this cell type induces a lot of alteration in what these cells
express; therefore, it is important to study the function of the genes in
their native disease environment without disrupting cell-cell and cell-
matrix interactions.
We aimed to identify novel modifiers of tissue fibrosis expressed in
myofibroblasts or their progenitors through RNA silencing in vivo.thor(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Targeted Genomic Screening Strategy
Intersection of differentially expressed genes upregulated in hepatic stellate cells
after chronic CCl4-induced liver injury and genes specific to renal pericyte/myofi-
broblast lineage after unilateral ureteral obstructions in mice. 169 commonly up-
regulated genes were subjected to a filter to exclude those with a well-known role in
fibrosis or with no human homolog or with unknown product, yielding 24 target
genes of interest.
www.moleculartherapy.orgAlthoughmuchmore challenging than conducting a cell-based screen
in vitro, this in vivo approach was pursued to enable the interrogation
of gene function in the context of the complex tissue environment and
thereby yield physiologically relevant fibrosis modifiers. In order to
achieve this objective, we employed recently generated transcrip-
tomes from myofibroblasts and their precursors in models of liver
and kidney injury and fibrosis.6,7 To achieve effective gene silencing
in vivo, we used small interfering RNA (siRNA) delivery with lipid
nanoparticles (siRNA-LNPs), an emerging technology for gene
silencing in vivo, particularly in the liver,8 and hence deployed this
technology in a model of liver fibrogenesis. The siRNA-LNP technol-
ogy has been previously used to show that silencing of the collagen
type I alpha 1 gene (Col1a1) reduced its mRNA levels and collagen
accumulation in liver fibrosis models.9,10 However, the use of
siRNA-LNP technology in a targeted assay for identifying novel
fibrosis modifiers has not yet been reported. Herein, we report our
use of a platform composed of novel siRNA targets, siRNA-LNP de-
livery technology, and CCl4-induced liver fibrosis, resulting in the
identification of novel modifiers of fibrogenesis in vivo.
RESULTS
Targeted Genomic Screening Strategy
We aimed to silence genes in key fibrogenic cell lineages, myofibro-
blasts, and pericytes to identify novel mediators of tissue fibrosis.
Candidate genes were selected by the intersection of gene expression
datasets for this cell lineage in two different organ systems. We iden-
tified genes that were commonly at least 2-fold upregulated in acti-
vated HSCs isolated from livers of mice treated with CCl4 for
2 months6 and myofibroblasts and pericytes, their precursors, in
the mouse kidney 2 and 5 days after unilateral ureteral obstruction
(UUO).7 169 genes met this criterion. We excluded transcripts that
were not associated with a gene product, had no human homolog,
or had well-known functions in fibrosis (Figure 1). Ultimately, we un-
biasedly tested 24 genes by siRNA-mediated gene knockdown (KD)
in vivo (Table S1).
Establishment of CCl4-Induced Liver Fibrosis and Validation of
the siRNA KD Approach in Mice
CCl4-induced liver injury and fibrosis in mice is a well-characterized
model consisting of repeated CCl4 administration that injures hepa-
tocytes, followed by a fibrogenic reaction. HSCs are activated to
expand, differentiate to myofibroblasts, and produce increased levels
of ECM and pro-inflammatory mediators, thereby also promoting
macrophage accumulation; all of these reactions constitute a coordi-
nated response to tissue injury and the progressive accumulation of
collagen. We found that animals dosed orally with 1 mL/kg of CCl4
in mineral oil on day 0 and day 7 and euthanized on day 10 exhibited
significant liver fibrosis based on increased picrosirius red (PSR) and
collagen immunopositivity in liver tissue as compared to vehicle-
treated mice. Percent area of tissue immunoreactive with aSMA,
the hallmark of myofibroblasts, and IBA-1, a macrophage-specific
marker, were also increased in CCl4-treated animals, suggesting an in-
crease in myofibroblasts and macrophage numbers in the tissue (Fig-
ures S1A–S1C). Corresponding to increased collagen deposition intissue, Col1a1 mRNA was markedly upregulated (Figure S2A). The
assessment of Col1a1 mRNA levels was used as an expedient
approach to functionally assess a relatively large number of siRNA
targets and flag fibrogenic genes of interest.
Given the siRNA-LNP delivery system targets multiple liver cell
types, including HSCs, hepatocytes, Kupffer cells, but not endothelial
cells,11–14 we validated the ability to KD genes expressed in HSCs in
mice using siRNA-LNPs (Figures S1D–S1H). Mice were injected with
a single dose of siRNA-LNP (1 mg/kg) against Reelin (Reln-LNPs), a
gene prominently expressed in HSCs.15 Animals receiving Reln-
LNPs, but not Luc-LNPs (negative control), showed significant reduc-
tion in Reln mRNA in both oil- and CCl4-treated animals (Fig-
ure S1E). We also demonstrate the ability to KD the HSC-specific
gene Col1a1 in liver. Col1a1-LNP reduced Col1a1 mRNA by 50%,
with no effect on RelnmRNA. Because the TGF-b pathway is a recog-
nized fibrogenic mediator, we tested whether KD of transforming
growth factor beta receptor 1 (Tgfbr1) decreased the transcription
and accumulation of collagen. Indeed, administration of Tgfbr1-
LNPs and Col1a1-LNPs, but not Luc-LNPs, reduced the transcription
of Col1a1 mRNA (Figure S1F) as well as collagen accumulation (Fig-
ures S1G and S1H).
To test the role of genes identified in our transcriptomic analysis, we
modified the siRNA administration protocol to allow pre-existingMolecular Therapy: Nucleic Acids Vol. 7 June 2017 315
Figure 2. Analysis of Fibrosis Modifiers
(A) Schematic of the experimental design showing ani-
mals dosed with CCl4 on day 0 and day 7, siRNA-LNPs
administered on day 7, 3, 2, and 6, and liver tissue
analyzed on day 10. (B–D) Graphs show the effect of
siRNA-KD of the indicated genes (x axis) on the accu-
mulation of collagen (% PSR positive area/total tissue
area) (B), % aSMA immunopositive area/total tissue
area (C), and % IBA-1 positive area/total tissue area (D)
relative to that obtained with Luc-LNPs administered in
CCl4-treated mice in the same experiment. Each symbol
represents an individual animal. Data are displayed as
mean ± SD. Statistically significant differences were
evaluated using one-way ANOVA and Dunnett’s post
test. Adjusted P values of less than 0.05 were considered
statistically significant with *p < 0.05; **p < 0.01; ***p <
0.001; and ****p < 0.0001. (E) Representative micro-
graphs of PSR (left panel), aSMA (middle panel), and
IBA-1 (right panel) immunoreacted liver section of CCl4/
Luc-LNP (upper row) or CCl4/Egr2-LNP (lower row)
treated animals. Scale bar, 1 mm.
Molecular Therapy: Nucleic Acidsprotein to be turned over and therefore achieve pre-clearance of pro-
teins encoded by the genes of interest and ensure continued KD
throughout the experiment (Figure 2A). We first used Luc-LNPs to
validate this protocol for detecting differences between oil- and
CCl4-treated cohorts, with respect to the levels of Col1a1 mRNA,
our primary parameter for defining target genes. We similarly evalu-
ated differences in the mRNA levels for a panel of other genes (Fig-
ure S2A). The strictly standardized mean difference (SSMD) values
for Col1a1, collagen type III alpha 1 (Col3a1), tissue inhibitor of met-
alloproteinases 1 (Timp1), and platelet derived growth factor receptor
beta (Pdgfrb), but not Tgfbr1, integrin subunit alpha M (Itgam), or
alpha-actin-2 (Acta2), suggested that these genes were suitable to
use as readout genes (Figure S2B).
Identification of Fibrosis Modifiers
Having established the suitability of the CCl4 treatment with the
siRNA-LNP KD platform, we proceeded to test our candidate genes.
We tested the effect of KD of 24 individual genes in vivo (Figure 2A).
We identified seven genes that significantly reduced the amount of
Col1a1 mRNA (Table 1). Five of these seven genes, namely, early
growth response 2 (Egr2), FK506-binding protein (Fkbp10), ATPase
Na+/K+ transporting subunit alpha 2 (Atp1a2), follistatin like 1
(Fstl1), and hyaluronan synthase 2 (Has2), were silenced by 75%–
100% in whole liver tissue and significantly reduced Col1a1 mRNA316 Molecular Therapy: Nucleic Acids Vol. 7 June 2017levels. Silencing of these genes did not elicit
any overt toxicity, as measured by body weight
loss (Figure S3). Because the other 19 genes did
not meet these criteria (Tables 1 and S1), we
focused on further analyzing the five modifiers
of fibrosis.
The KD of the transcription factor (TF) Egr2
had the broadest effect by reducing the levelsof Col1a1 and Col3a1mRNA as well as the percent area immunopos-
itive for aSMA, IBA-1, and collagen proteins, although the reduction
in collagen by half did not achieve significance (Figure 2; Table 1).
Egr2 silencing also reduced Pdgfrfb mRNA levels (Figure 3A), sug-
gesting a mechanism of decreased fibrosis and macrophage accumu-
lation due to reduced expansion of activated HSCs. Given that Egr2
has structural similarities to its family members, Egr1 and Egr3, we
confirmed the specificity of the Egr2 siRNA by transfecting human
293T cells with plasmids encoding mouse Egr1, Egr2, or Egr3 under
the transcriptional control of the CMV promoter. In the tested
construct, the expression of mouse Egr1, Egr2, and Egr3 is not under
the control of the endogenous promoter. Thus, reduction in gene
expression is due to the binding of the siRNA Egr2 to the mRNA. Us-
ing the same Egr2 siRNA that was used for the in vivo experiments, we
found that this siRNA reduced Egr2 mRNA levels, but not Egr1 or
Egr3 mRNA, unambiguously demonstrating that Egr1 and Egr3
were not targeted by our Egr2 siRNA (Figures S4A–S4C). Interest-
ingly, even though the siRNA against Egr2 was specific, Egr2-LNP
treatment in vivo also reduced Egr1 and Egr3 mRNA levels (Figures
S4D–S4F), suggesting transcriptional co-regulation of EGR family
members.
Similar to Egr2, KD of Fkbp10 or Atp1a2 reduced the collagen and
IBA-1 positive areas as did that of Egr2 (Figure 2; Table 1); however,
Table 1. Fibrosis Modifiers in CCl4-Induced Liver Fibrosis Identified by siRNA KD
Target KD (%)
Relative
Col1a1
mRNA (%)
Relative
Col3a1
mRNA (%)
No. of Other
Readout
Genes
Relative
Positive PSR
Area (%)
PSR Non-
adjusted
p Value
Relative
aSMA-Positive
Area (%)
aSMA Non-
adjusted
p Value
Relative IBA-
1-Positive
Area (%)
IBA-1 Non-
adjusted
p ValueUp Down
Egr2 94.1 15.1* 46.7** 1a 54.5 0.0145 14.8* 0.0034 15.4** 0.0241
Fkbp10 74.7 25.1**** 76.1 1a 64.4 0.0150 79.4 0.3322 16.5*** 0.0036
Atp1a2 97.8 62.1** 99.9 1b 51.4*** <0.0001 130.9 0.1167 47.1**** <0.0001
Fstl1 78.6 39.3** 96.9 1b 48.5** 0.0009 179.7 0.0800 12.7**** 0.0034
Has2 100 29.1**** 97.3 1b 65.6 0.0155 229.5**** <0.0001 8.1**** 0.0011
Dpysl3 46.7 40.7** 96.1 1b 100.3 0.9850 20.3 0.0628 26.1*** 0.0122
Crlf1 24.8 54.7* 86.5 2a,c 101.1 0.9998 68.5 0.3232 118.6* 0.0053
The gene-specific KD of the indicated gene itself as well as the relative gene expression of Col1a1 and Col3a1 compared to Luc-LNP-treated animals were tabulated. Statistically
significant differences were evaluated using one-way ANOVA and Dunnett’s post test. Adjusted p values < 0.05 were considered statistically significant, with *p < 0.05; **p < 0.01;
***p < 0.001; and ****p < 0.0001. Non-adjusted p values are also tabulated. Dpysl3, dihydropyrimidinase like 3; Crlf1, cytokine receptor like factor 1.
aPdgfrb.
bTimp1.
cTgfbr1.
www.moleculartherapy.orgKD of Fkbp10 or Atp1a2 did not alter the percent immunopositivity
for aSMA. Fkbp10 KD also decreased Pdgfrb mRNA levels, but this
effect was somewhat weaker than that of Egr2 (28% versus 45% reduc-
tion; Figures 3A and 3B), possibly accounting for its lack of effect on
aSMA immunopositivity. Atp1a2 KD also decreased Timp1 mRNA
levels (Figure 3C). These results suggest that Egr2, Fkbp10, and
Atp1a2 regulate fibrogenesis through different mechanisms.
KD of either of the two other fibrosis modifiers, Fstl1 and Has2,
decreased Col1a1 mRNA levels as well as macrophage and collagen
accumulation in the tissue, although Has2 KD did not achieve signif-
icance for the latter (Figure 2). Notably, KD of these genes showed
increased amounts of aSMA immunopositivity, which was highly sig-
nificant for Has2 KD, suggesting increased numbers of myofibro-
blasts. Corresponding with the increased myofibroblasts, we detected
higher levels of the Timp1mRNA in the livers of both Fstl1 and Has2
KD animals (Figures 3D and 3E). Despite the increased myofibroblast
and Timp1 mRNA levels, Fstl1 KD significantly reduced collagen
accumulation. In order to understand these findings, we also conduct-
ed in parallel in vitro studies and showed that three independent
FSTL1 siRNAs reduced COL1A1 mRNA levels. Thus, the direct
reduction of collagen transcription may be sufficient to reduce overall
collagen accumulation, despite the elevated number of myofibroblasts
and reduced collagen degradation (Figure S5).
Silencing of EGR2 in Human HSCs Reduces Expression of
Fibrogenic Genes
EGR2 emerged as the strongest modifier of fibrosis in the CCl4 liver
fibrosis/siRNA KD platform. We aimed to directly demonstrate
that EGR2 KD in an HSC would reduce COL1A1 and PDGFRB
mRNA levels. We tested the effect of EGR2 KD in the human HSC
line LX-2 using three independent siRNAs (Figure 4). This experi-
ment required a different siRNA to be used because no speciescross-reactive siRNA was designed (see Materials and Methods).
All siRNAs against ERG2 reduced its mRNA levels as well as
COL1A1 and PDGFRB mRNA levels. These results are consistent
with the effect of Egr2 KD in our in vivo CCl4 assay platform. As ex-
pected, KD of COL1A1 reduced its own expression, but not that of
EGR2. Interestingly, COL1A1 silencing also reduced PDGFRB
mRNA levels, suggesting a regulatory feedback loop. Taken together,
these data support that EGR2 is fibrogenic in both rodents and
humans.
DISCUSSION
There are currently limitations in the understanding of pathophysio-
logical mechanisms underlying fibrotic diseases. Myofibroblasts are
key effectors of fibrosis and therefore the elucidation of pathways
that promote this cell lineage would be a significant advance in the
field. Here, we report the use of a targeted in vivo siRNA KD platform
to identify novel mediators of fibrogenesis. We leveraged novel
biology-targeting genes upregulated during liver and kidney fibrosis
in myofibroblasts and their progenitors and siRNA-LNP technology
to silence these genes in CCl4-induced liver injury and fibrosis in
mice. We identified five genes, namely Egr2, Atp1a2, Fkbp10, Fstl1,
and Has2, which modified fibrogenesis in this system because their
KD reduced Col1a1 mRNA levels and collagen accumulation in the
liver. Prior to our study, Egr2, Atp1a2, and Fkbp10 had not been func-
tionally validated in fibrosis in vivo, and our study is the first to vali-
date Fstl1 andHas2 in liver fibrosis. We further directly demonstrated
that Egr2 KD in human HSCs reduced the expression of fibrotic
genes. We conclude that in vivo siRNA KD using siRNA-LNP is a
powerful tool to identify disease-relevant modifiers in vivo.
Studying myofibroblasts is extremely difficult because they are in
direct contact withmultiple cell types, including other myofibroblasts,
myeloid cells, mesothelial cells, endothelial cells, epithelial cells, andMolecular Therapy: Nucleic Acids Vol. 7 June 2017 317
Figure 3. Effect of Gene Silencing on mRNA Levels of a Panel of Readout Genes
(A–E) qPCR data of indicated readout genes (x axis) of animals that have received siRNA-LNPs targeting Egr2 (A), Fkbp10 (B),Atp1a2 (C), Fstl1 (D), orHas2 (E) were plotted as
percentage of Luc-LNP treated animals within the same experiment. n = 4–15 animals per group. Data are presented asmean ± SD. Statistical comparisons were performed
using one-way ANOVA and Dunnett’s post test. Statistical differences are indicated as *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001. ND, not detected.
Molecular Therapy: Nucleic Acidscirculating fibrocytes in situ.16 Myofibroblasts respond to chemo-me-
chanical stimuli, and therefore disruption of their native environment
during cell isolations alters their activation state. To circumvent these
shortcomings, we silenced target genes in vivo by systemic adminis-
trating siRNA-LNPs. This approach allowed us to study functional
consequences of silencing of specific genes of interest in vivo in their
native environment. It is of note that our siRNA-LNP delivery
approach allows us to silence gene expression in HSCs; however,
this LNP formulation also targets other cells in the liver, including
Kupffer cells and hepatocytes, but not endothelial cells.11–14 There-
fore, we cannot rule out the contribution of gene silencing in Kupffer
cells and hepatocytes on the anti-fibrotic outcome.
Our strategy to identify novel players in tissue fibrosis took advantage
of recent transcriptomic datasets for myofibroblasts and their precur-
sors isolated from fibrotic liver or kidney in mouse models.6,7 Using318 Molecular Therapy: Nucleic Acids Vol. 7 June 2017siRNA-LNP delivery technology, we tested the effect of gene silencing
in a physiologically relevant context in vivo. We employed a CCl4
administration model that featured significant collagen accumulation
and established several robust RNA and histological measures of fi-
brogenic activity to identify fibrosis modifiers. Using the criteria of
significant reduction of Col1a1 mRNA levels, we identified seven
modifiers of interest out of 24 tested genes. Of greatest interest are
those that also reduced collagen accumulation in the tissue, namely,
Egr2, Atp1a2, Fkbp10, Fstl1, and Has2. Notably, these five genes
were themost strongly silenced in vivo (by 75% or greater) that signif-
icantly reduced Col1a1mRNA levels. It is possible that we might have
achieved a greater degree of in vivo gene silencing for other target
genes with a higher dose or a different dosing paradigm. Thus,
although we cannot draw conclusions about the functional role of
genes whose silencing was incomplete, our results clearly identify
five genes as novel fibrogenic mediators in liver fibrosis in vivo. These
Figure 4. KD of EGR2 Reduces COL1A1 and
PDGFRB mRNA Levels in Human HSC Line
(A–C) Graphs show the effect of siRNA-KD of the indi-
cated genes (x axis) on relative mRNA levels of EGR2 (A),
COL1A1 (B), and PDGFRB (C). The effect of three inde-
pendent siRNAs against EGR2 is shown. Data are pre-
sented as mean ± SD. Statistical comparisons were
performed using one-way ANOVA and Dunnett’s post
test. Statistical differences are indicated as ***p < 0.001
and ****p < 0.0001. ns, not significant.
www.moleculartherapy.orggenes fell into different groups based on the effects of their silencing
on a mini mRNA array and histological measures. We propose
grouping them as follows: Egr2, a gene with potential function in
HSC expansion; Atp1a2 and Fkbp10, genes that regulate mechano-
sensing; and Fstl1 and Has2, genes involved in matrix-cell signaling.
Egr2, a TF of the EGR family, emerged as the strongest effector in the
siRNA screen. EGR TFs are important for the induction of cellular
programs, including cell proliferation, differentiation, and death, in
response to stimuli such as cytokines, growth factors, and toxic sub-
stances.17–19 Egr2 has not been previously reported to play a role in
tissue fibrosis in vivo.20 Rather, EGR2 is prominently known for its
role in early myelination of the peripheral nervous system in humans
and mice.21–23
Egr2 KD silenced its expression by 94%, reduced Col1a1 and Col3a1
mRNA levels, and diminished accumulation of myofibroblasts and
macrophages, each to 15% of control. Liver fibrosis was also alleviated
because collagen accumulation was reduced by half. Thus, our
demonstration of reduced fibrogenic activity by Egr2 silencing reveals
a novel EGR2 function. The downregulation of Pdgfrb mRNA levels
by 45% suggests that EGR2may promote HSC expansion. This mech-Molecularanism would explain the reduced aSMA-ex-
pressing HSC and thereby reduced signals for
macrophage accumulation, all of which may
have contributed to the reduction in fibrosis.
Importantly, we also directly demonstrate that
EGR2 KD in a human HSC line reduces
COL1A1 and PDGFRB transcripts, supporting
the regulation of a fibrogenic program in
HSCs by this TF. The comparatively weaker ef-
fect of COL1A1 silencing in vitro (50%) versus
in vivo siRNA-LNP- mediated KD (80%) of
EGR2 is due to the use of different delivery
methods as well as the use of different siRNA se-
quences to achieve gene silencing in human cells
versus in vivo in mice. Interestingly, COL1A1
KD also reduced PDGFRB mRNA levels.
Because ECM accumulation and expression of
PDGFRb are linked,24 it is feasible that
decreased collagen production would decrease
PDGFRb expression in a feedback loop. Therelevance of our finding to fibrogenesis in humans is also supported
by a prior in vitro study, in which overexpression of Egr2 in human
skin fibroblasts upregulated collagen gene expression and myofibro-
blast differentiation, and these profibrotic TGF-b-induced responses
were attenuated by Egr2-depletion.25
Egr2 targeting in our in vivo assay platform revealed interesting re-
sults. We unambiguously confirmed that our siRNA is specific for
Egr2 (Figures S4A–S4C) and also found that Egr2 KD in human
HSCs reduces COL1A1 and EGR2, but not EGR1 or EGR3 mRNA
(data not shown), confirming the anti-fibrotic effect. However, in vivo
Egr2KD also decreased themRNA levels of Egr1 and Egr3, supporting
the co-regulation of these transcription factors. It has been shown
previously in vitro that overexpression of Egr1 induced Egr2 and
Egr3 expression and likewise Egr3 overexpression induced Egr1 and
Egr2 expression, whereas overexpression of Egr2 did not have such
an effect.25–27 Here, we report that Egr2 KD also reduces Egr1 and
Egr3 mRNA levels in vivo, a novel aspect of EGR TF co-regulation.
Although Egr2 has not been previously reported to play a role in tissue
fibrosis in vivo,20 Egr1 and Egr3 have been implicated in the fibrotic
response in vitro and in vivo previously.27–29 Therefore, the extent
of the anti-fibrotic effect may be due the co-regulation of EGR TF.Therapy: Nucleic Acids Vol. 7 June 2017 319
Molecular Therapy: Nucleic AcidsAtp1a2 and Fkbp10 were identified as fibrogenic modulators, with
mechanisms of action distinct from that of Egr2. ATP1A2 is the large
catalytic subunit of an enzyme that catalyzes the hydrolysis of ATP,
coupled with the exchange of Na+ and K+ ions across the plasma
membrane. ATP1A2 has a known function in the contractility of skel-
etal and cardiac muscle.30 On the basis of our results, it is intriguing to
speculate that Atp1a2 silencing may have reduced the contractility of
myofibroblasts, effectively mimicking their behavior in a more
compliant matrix environment and hence resulting in a less fibro-
genic program.31,32 Supporting this theory, we found that Atp1a2
KD reduced fibrogenesis in vivo by significantly limiting the tran-
scription of the Col1a1 and Timp1 genes, macrophage accumulation,
and collagen deposition. However, in contrast to Egr2, Atp1a2
silencing had no effect on aSMA expression. This pattern suggests
that the myofibroblasts are generated but have reducedmechanosens-
ing function. This theme of altered mechanosensing may also explain
the alleviated fibrosis upon silencing of Fkbp10. FKBP10 is a molecu-
lar chaperone in the endoplasmatic reticulum that directly interacts
with collagen I, contributing to thematuration andmolecular stability
of type I procollagen, promoting normal secretion, stable inter-mo-
lecular crosslinking, and collagen deposition in the ECM.33 FKBP10
has a well-established role in bone mass in humans and mice, but
its role in tissue fibrosis is largely unexplored.34 Fkbp10/ mouse
embryos are post-natally lethal and display reduced collagen cross-
linking in calvarial bones.35 In this study, we report our novel finding
that Fkbp10 silencing reduces collagen deposition to 64%; however,
we found no reduction in aSMA expression. We speculate that
Fkbp10 silencing alters the quantity or crosslinking of the ECM and
thereby alters mechanosensing. Consistent with our in vivo results,
a prior in vitro study showed that inhibition of FKBP10 in primary
human fibroblasts from pulmonary fibrosis patients attenuates
expression of pro-fibrotic genes and decreases collagen secretion.36
Thus, our findings expand the scope of Atp1a2 and Fkbp10 functions
by demonstrating their novel roles in fibrogenesis in vivo.
Fstl1 andHas2 silencing also affected multiple fibrogenic readouts in
our assay platform, but resulted in a pattern distinct from that of
Egr2, Atp1a2, and Fkbp10. Both Fstl1 and Has2 silencing reduced
Col1a1 mRNA, macrophage accumulation, and collagen deposition
but counterintuitively increased myofibroblast density as well as the
level of Timp1 mRNA, a profibrotic pathway. FSTL1 is a TGF-
b-inducible, secreted, matricellular glycoprotein belonging to the
secreted protein acidic rich in cysteines (SPARC) family, with pleio-
tropic functions.37–39 During the course of our current study, it was
reported that haplodepletion of Fstl1 or a neutralizing anti-FSTL1
antibody reduced bleomycin-induced pulmonary fibrosis.38 We
found that Fstl1 gene silencing reduced collagen transcription and
accumulation in the context of liver fibrosis but surprisingly
increased myofibroblast density, possibly reflecting a compensatory
feedback loop. We hypothesize that the overall reduction in collagen
accumulation is a direct result of decreased collagen production by
Fstl1 silencing, so that the increased number of myofibroblasts and
reduced activity of collagen degradation would still result in
decreased overall collagen accumulation. Indeed, KD of FSTL1 in320 Molecular Therapy: Nucleic Acids Vol. 7 June 2017the human HSC line LX-2 resulted in decreased levels of COL1A1
mRNA.
Like Fstl1, silencing of Has2 resulted in unexpected effects, also likely
through a matrix-modifying mechanism. HAS2 is one of three isoen-
zymes responsible for cellular hyaluronan (HA) synthesis, a matrix
component normally highly abundant in joint synovium. HA is
well known for its role in wound healing.40,41 Has2 has been previ-
ously reported to be pathological in the bleomycin-induced lung
fibrosis model, in which mesenchymal cell-specific deletion of Has2
abrogated myofibroblast accumulation and inhibited the develop-
ment of lung fibrosis.42We show thatHas2 silencing also reduces liver
fibrosis. Has2 silencing also unexpectedly augmented myofibroblast
density. Taken together, our studies have identified Fstl1 and Has2
as fibrosis modifiers in our in vivo liver fibrosis platform and reveal
surprising effects of silencing these genes, supporting their complex
role in the regulation of fibrogenesis.
To the best of our knowledge, our study is the first example of a tar-
geted siRNA assay for the discovery of novel fibrosis modifiers in vivo.
The results implicate five novel modulators of the fibrogenic process
in the liver and demonstrate the feasibility of siRNA-LNP for interro-
gating gene function in the liver. Because these genes are commonly
upregulated in pericytes and myofibroblasts in both liver and kidney
fibrosis models, these genes warrant follow-up to further explore their
function and mechanism of action in liver and other organs and
to inform their role in both physiological and pathophysiological
fibrosis.MATERIALS AND METHODS
Animal Experiments
All animal procedures were conducted in accordance with Cambridge
laws and the Institutional Animal Care and Use Committee approved
protocol No. 657. 8- to 10-week-old male BALB/c mice (Taconic
Bioscience) were given CCl4 by oral gavage (Sigma-Aldrich;
1 mL/kg dissolved in mineral oil) on days 0 and 7. Mineral oil alone
was used as a control. In some experiments, siRNA-LNPs were given
by tail vein injection. siRNA-LNPs were either given on day 6 at a
concentration of 1 mg/kg or on days 7, 3, 2, and 6 at 0.5 mg/kg.
These experiments were controlled with cohorts of mice that received
siRNA targeting Luciferase (Luc-LNPs) with oil or CCl4, respectively.
Animals were sacrificed on day 10 by CO2 asphyxiation, followed by
cardiac perfusion with 10 mL of PBS, and liver lobes were harvested
for qPCR and histopathological analysis.Gene Selection
Target fibrosis modifier genes were selected by intersecting transcrip-
tomic data generated from isolated HSCs of mice treated with CCl4
for 2 months, and genes specifically expressed in pericytes/myofibro-
blasts in the mouse kidney 2 and 5 days after UUO.6,7 169 genes were
common to both datasets and significantly upregulated at least 2-fold.
Among these, we excluded transcripts that were not associated
with a gene product, genes with no known human homolog, and
www.moleculartherapy.orgwell-knownmodifiers in fibrosis (validated in vivo by independent in-
vestigators), resulting in 24 genes for further evaluation.
siRNA Design and Synthesis
A set of ten siRNAs with canonical siRNA structures was defined for
each target gene.43 All siRNAs were directed against the coding
sequence of their respective target mRNA and perfectly matched all
known mRNA transcript variants of the target gene available in the
NCBI reference sequence database (RefSeq DB, release 65, May 2014).
The siRNAs used in this studywere designed to be a perfectmatch only
to their target mRNA and to havea 2mismatches within positions 2–
18 of the 19-mer sequence to any other genes. The design as described
above is sufficient to ensure specificity.44,45 Specifically, at least four
mismatches between the siRNA sequences of each of the genes of in-
terest (Atp1a2, Egr2, Fkbp10, Fstl1, and Has2) and the readout genes
Col1a1, Col3a1, Tgfbr1, Pdgfrb, and Timp1. Further, there were three
mismatches between Egr2 siRNA and Egr1 sequence and more than
four mismatches between Egr2 siRNA and Egr3 sequence.
The siRNA antisense strands lacked a seed region (nucleotides 2–7)
identical to a seed region (nucleotides 2–7) of known mouse miRNAs
(miRBase, release 20, June 2013). Additional similarity analysis showed
that there were at least four mismatches between the siRNA sequences
of each of the genes of interest (Atp1a2, Egr2, Fkbp10, Fstl1, andHas2)
and the readout genes Col1a1, Col3a1, Tgfbr1, Pdgfrb, and Timp1.
Further, there were three mismatches between Egr2 siRNA and Egr1
sequence and more than four mismatches between Egr2 siRNA and
Egr3 sequence. From siRNAs fulfilling those criteria, the siRNAs for
each final screening were selected for predicted activity based on anal-
ysis with proprietary algorithms (Axolabs, GmbH). In vivo grade
siRNAs were synthesized by Axolabs, as described elsewhere.46
siRNA In Vitro Screen
Each of the ten aforementioned siRNA molecules/target gene was
screened for its potency to KD gene expression in a cell-based re-
porter assay. For each target gene, the regions of their coding se-
quences targeted by the siRNAs were synthesized and inserted to
the 30 UTR of the firefly luciferase gene in pCMVluc(V) validation
vector (Origene), generating an mRNA transcript that encodes both
the luciferase (Luc) and the target gene when expressed in cells.
293T cells (ATCC) were co-transfected with the validation vector
and the siRNAs of interest using Lipofectamine 2000 (Thermo Fisher
Scientific) at 0.1-, 1-, and 10-nM concentrations to assess KD potency.
siRNA binding to the target gene leads to degradation of the mRNA
that encode both Luc and the target gene, resulting in reduced lucif-
erase expression. Luciferase expression was measured 24 hr post-
transfection in a functional assay using the Promega Luciferase Assay
System (Promega), and luciferase signal was detected using a
PerkinElmer EnVision Plate Reader (PerkinElmer). For each siRNA
tested, the efficiency of KD was calculated as percent of luciferase
signal compared to cells that were transfected with the validation vec-
tor for the target gene alone. The most potent siRNA for each target
gene (>90% luciferase reduction at 1 nM siRNA in vitro) was thenformulated as LNPs for in vivo application. The sequences of the
siRNAs that resulted in efficient KD (R75%) of their target gene
in vivo are provided in Table S2.
siRNA LNP Formulation
siRNA-LNPs were synthesized by mixing together an siRNA-con-
taining aqueous phase with a lipid-containing ethanol phase.
The aqueous phase contained siRNA in 10 mM citrate buffer
(pH 3). The ethanol phase contained ionizable lipid11 C12-200
(Wuxi AppTec), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC,
Avanti Polar Lipids), cholesterol (Sigma), and 1,2-dimyristoyl-sn-glyc-
ero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(C14 PEG 2000, Avanti) at a 50:10:38.5:1.5 molar ratio and 5:1
C12-200:siRNA weight ratio. The aqueous and ethanol phases were
mixed together at a 3:1 volume ratio in amicrofluidic chip device using
syringe pumps as previously described47 to a final siRNA concentra-
tion of 1 mg/mL. The resultant siRNA-LNPs were dialyzed overnight
in a 20,000 molecular weight cut-off (MWCO) cassette against 1x
PBS at 4C. On average, siRNA-LNPs had a mean diameter of
approximately 100–150 nm, with a polydispersity index between
0.1 and 0.2 as measured by Dynamic Light Scattering (ZetaSizer,
Malvern Instruments). The siRNA encapsulation efficiency (approx-
imately 60%) was determined using a modified Quant-iT Ribogreen
Assay (Invitrogen) as previously described.48 This siRNA delivery
system can target multiple liver cell types, including hepatocytes,
monocytes, tissue macrophages, dendritic cells (DCs), and myofi-
broblasts/pericytes.
RNA Expression Analysis
RNA was extracted from liver lobes with Trizol (Thermo Fisher Sci-
entific), followed by on-column DNase digestion using RNeasy Mini
Kits and RNase free DNase sets (both from QIAGEN). cDNA was
generated using the High-Capacity cDNA Reverse Transcription
Kit, and qPCR analysis was performed using pre-designed TaqMan
primer probes (Table S3) on the QuantStudio 12K Flex Real-Time
PCR System (all from Thermo Fisher Scientific) to determine the
expression levels of siRNA target genes and a panel of readout genes.
All procedures were conducted following the manufacturer’s proto-
cols. The relative expression of each gene was normalized to mouse
or human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) us-
ing the 2-DDCT method, and the mean expression of each gene in the
control group was set to 100%.
Histopathology
Livers lobes were fixed in 10% neutral buffered formalin and
embedded in paraffin. 5-mm sections were stained with PSR using
an automated Leica system according to standard protocols. Immu-
nohistochemistry (IHC) was performed with the Ventana system.
Anti-alpha-Smooth muscle actin (aSMA) IHC was performed with
fluorescein isothiocyanate (FITC)-labeled mouse monoclonal anti-
body 1A4, followed by an anti-FITC antibody and periodic acid-
Schiff (PAS) counterstain (Abcam). Anti-IBA-1 and anti-COL1A1
IHC was performed using rabbit polyclonal antibodies (cat. # 019-
19741, Wako, and Genetex, cat. # GTX41286).Molecular Therapy: Nucleic Acids Vol. 7 June 2017 321
Molecular Therapy: Nucleic AcidsImage analysis was performed by writing custom algorithms with
Visiopharm software. The IBA-1 positive area was limited to infil-
trating macrophages by differentiating isolated single cells (largely
Kupffer cells lining sinusoids) from larger round cells in clusters
(periportal, largely infiltrating macrophages, sometimes filled with
mineral). De novo interstitial aSMA was differentiated from endoge-
nous aSMA in muscular arteries by performing a PAS counterstain
and then programming the algorithm to distinguish vascular
morphology for exclusion from quantification. Exclusion of muscular
arteries was similarly performed on sections with anti-COL1A1 IHC.siRNA Gene Silencing in Cell Lines
The human HSC line LX-2 (EMD Millipore) was transfected
with siRNAs against EGR2, COL1A1, or Luc with Lipofectamine
RNAiMAX reagent following the manufacturer’s protocol. We used
the following predesigned siRNAs (listed as siRNA ID): EGR2:
s4540, s4541, and s4542; COL1A1: s3276; Luc: AM4629; and
FSTL1: s22032, s22033, and s22034 (Thermo Fisher Scientific).
RNA was isolated on day 2 after transfection using RNeasy kits
with on-column DNase digestion (QIAGEN). cDNA synthesis and
qPCR was performed as stated above.
293T cells (ATCC) were co-transfected with pCMV-Egr1, pCMV-
Egr2, or pCMV-Egr3 (Origene) and either Silencer Select Negative
Control No. 1 siRNA (Thermo Fisher Scientific) or siRNA against
Egr2 (Axolabs). RNA was isolated 24 hr after co-transfection using
RNeasy plus kits (QIAGEN). cDNA synthesis and qPCR was per-
formed as stated above.Statistical Analysis
Datasets are presented as mean ± SD. Statistical significance was as-
sessed by two-tailed, unpaired Student’s t test for comparison of two
groups or by one-way ANOVA, followed by the Dunnett’s multiple
comparisons test for more than two groups. Differences with adjusted
P values of less than 0.05 were considered statistically significant.
Non-adjusted P values were listed to convey trends (Table 1).
We used an SSMD49 method to analyze the suitability of the mRNA
readout genes in our siRNA-LNP/CCl4 liver fibrosis platform (Fig-
ure S2). The SSMD method was used to calculate the median of
differences divided by the standard deviation of the differences
between the group treated with oil and the control siRNA targeting
Luciferase (oil/Luc-LNP) and versus CCl4/Luc-LNP. It represents
the average fold change penalized by the variability of the fold
change across animals. SSMD is a suitable method because it takes
the variability between animals into account. For our study,
a threshold of b < 1.5 was taken as the cut-off value for suitable
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